Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance

Abstract Background Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many genetic causes, and recent studies suggest the important role of ESR1 mutatio...

Full description

Bibliographic Details
Main Authors: Li Li, Ling Lin, Jamunarani Veeraraghavan, Yiheng Hu, Xian Wang, Sanghoon Lee, Ying Tan, Rachel Schiff, Xiao-Song Wang
Format: Article
Language:English
Published: BMC 2020-08-01
Series:Breast Cancer Research
Subjects:
ESR1-CCDC170
Endocrine resistance
Luminal breast cancer
HER2
SRC
Online Access:http://link.springer.com/article/10.1186/s13058-020-01325-3

Internet

http://link.springer.com/article/10.1186/s13058-020-01325-3

Similar Items